Recognition and clinical implications of high prevalence of migraine in patients with Brugada syndrome and drug-induced type 1 Brugada pattern

Basit Öğe Kaydı
dc.contributor.authorHasdemir, Can
dc.contributor.authorGokcay, Figen
dc.contributor.authorOrman, Mehmet N.
dc.contributor.authorKocabas, Umut
dc.contributor.authorPayzin, Serdar
dc.contributor.authorSahin, Hatice
dc.contributor.authorAntzelevitch, Charles
dc.date.accessioned2020-12-01T11:57:50Z
dc.date.available2020-12-01T11:57:50Z
dc.date.issued2020
dc.departmentEge Üniversitesien_US
dc.description.abstractIntroduction We have previously reported high 1-year prevalence of migraine in patients with atrial arrhythmias associated with DI-type 1 BrP. the present study was designed to determine the lifetime prevalence of migraine in patients with Brugada syndrome (BrS) or drug-induced type 1 Brugada pattern (DI-type 1 BrP) and control group, to investigate the demographic and clinical characteristics, and to identify clinical variables to predict underlying BrS/DI-type 1 BrP among migraineurs. Methods and Results Lifetime prevalence of migraine and migraine characteristics were compared between probands with BrS/DI-type 1 BrP (n = 257) and control group (n = 370). Lifetime prevalence of migraine was 60.7% in patients with BrS/DI-type 1 BrP and 30.3% in control group (p = 3.6 x 10(-14)). on stepwise regression analysis, familial migraine (odds ratio [OR] of 4.4; 95% confidence interval [CI]: 2.0-9.8; p = 1.3 x 10(-4)), vestibular migraine (OR of 5.4; 95% CI: 1.4-21.0); p = .013), migraine with visual aura (OR of 1.8; 95% CI: 1.0-3.4); p = .04) and younger age-at-onset of migraine (OR of 0.95; 95% CI: 0.93-0.98); p = .004) were predictors of underlying BrS/DI-type 1 BrP among migraineurs. Use of anti-migraine drugs classified as "to be avoided" or "preferably avoided" in patients with BrS and several other anti-migraine drugs with potential cardiac I-Na/I-Ca channel blocking properties was present in 25.6% and 26.9% of migraineurs with BrS/DI-type 1 BrP, respectively. Conclusion Migraine comorbidity is common in patients with BrS/DI-type 1 BrP. We identify several clinical variables that point to an underlying type-1 BrP among migraineurs, necessitating cautious use of certain anti-migraine drugs.en_US
dc.description.sponsorshipNIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HL47678, HL138103, HL152201]; W.W. Smith Charitable Trust; Wistar and Martha Morris Funden_US
dc.description.sponsorshipCA was supported by grants from the NIH (HL47678, HL138103, and HL152201), W.W. Smith Charitable Trust and Wistar and Martha Morris Fund.en_US
dc.identifier.doi10.1111/jce.14778en_US
dc.identifier.issn1045-3873
dc.identifier.issn1540-8167
dc.identifier.pmid33058326en_US
dc.identifier.scopus2-s2.0-85093533384en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.1111/jce.14778
dc.identifier.urihttps://hdl.handle.net/11454/61827
dc.identifier.wosWOS:000581123500001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofJournal of Cardiovascular Electrophysiologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBrugada syndromeen_US
dc.subjectdrug&#8208en_US
dc.subjectinduced type 1 Brugada ECG patternen_US
dc.subjectdrugsen_US
dc.subjectepidemiologyen_US
dc.subjectgeneticsen_US
dc.subjectmigraineen_US
dc.titleRecognition and clinical implications of high prevalence of migraine in patients with Brugada syndrome and drug-induced type 1 Brugada patternen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu